Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients

Fig. 4

Factors affecting 75% reduction of portal vein thrombosis volume. a Plasma AT-III level was 59.5 ± 1.9% and 60.4 ± 14.8% in the ineffective and effective groups, respectively, with no significant difference. b No significant difference is seen regarding whether pretreatment AT-III level was within normal range or not in both groups. c No significant difference is seen regarding use of AT-III or not. d Significantly more cases where treatment was effective for AT-III level > 70% during the treatment period (P = 0.0426). e No significant difference is seen between partial or complete portal vein occlusion. f No significant difference is seen in comparisons between Bauer’s Classification grade II and III patients and grade IV patients. g Although the difference was not significant there were 8 patients (19.5%) with completely dissolved thrombus among Bauer’s Classification II and III patients but none among the Bauer’s Classification IV patients

Back to article page